Results 371 to 380 of about 104,116 (405)
Some of the next articles are maybe not open access.
Supportive Care in Cancer, 2005
Buprenorphine is a broad spectrum, highly lipophilic, and long-acting partial mu opioid receptor agonist that is noncross tolerant to other opioids. Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases.
openaire +3 more sources
Buprenorphine is a broad spectrum, highly lipophilic, and long-acting partial mu opioid receptor agonist that is noncross tolerant to other opioids. Buprenorphine can be given by several routes. Metabolism is through CYP3A4 and CYP2C8 and by conjugases.
openaire +3 more sources
Drug and Alcohol Review
AbstractIntroductionThis case series records a cohort of patients treated with transdermal buprenorphine patches as part of a buprenorphine microdose induction protocol to transition from methadone to buprenorphine in a community setting. This has historically been a difficult process to manage in community settings and this case series explored a ...
Thileepan Naren +3 more
openaire +2 more sources
AbstractIntroductionThis case series records a cohort of patients treated with transdermal buprenorphine patches as part of a buprenorphine microdose induction protocol to transition from methadone to buprenorphine in a community setting. This has historically been a difficult process to manage in community settings and this case series explored a ...
Thileepan Naren +3 more
openaire +2 more sources
Buprenorphine: Beyond Methadone?
Psychiatric Services, 1991This month's guest authors are affiliated with the substance abuse treatment and treatment research unit of the Connecticut Mental Health Center and the department of psychiatry at Yale University School of Medicine, where Dr. Rosen is instructor and Dr. Kosten is associate professor.
Marc I. Rosen, Thomas R. Kosten
openaire +3 more sources
Anesthesia for Patients on Buprenorphine
Anesthesiology Clinics, 2010Opioid abuse is a devastating, costly, and growing problem in the United States, and one for which treatment can be complicated by barriers such as access to care and legal issues. Only 12% to 15% of the opioid-dependent population is enrolled in methadone maintenance programs.
Clifford Gevirtz +2 more
openaire +3 more sources
Buprenorphine for Chronic Pain
Journal of Pain & Palliative Care Pharmacotherapy, 2013Questions from patients about pain conditions, analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The use of transdermal buprenorphine for chronic pain management is discussed. A brief history of the medication is provided.
Raul Calderon, David J Copenhaver
openaire +3 more sources
Journal of the American Academy of Child & Adolescent Psychiatry, 2023
Paul E.A. Glaser +3 more
openaire +1 more source
Paul E.A. Glaser +3 more
openaire +1 more source
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
DrugsBuprenorphine is an agonist at the mu opioid receptor (MOR) and antagonist at the kappa (KOR) and delta (DOR) receptors and a nociceptin receptor (NOR) ligand. Buprenorphine has a relatively low intrinsic efficacy for G-proteins and a long brain and MOR dwell time.
openaire +2 more sources